Ovarian clear cell cancer

disease

On this page

Also known as malignant ovarian clear cell neoplasmmalignant ovarian clear cell tumormalignant ovarian clear cell tumour

Summary

Ovarian clear cell cancer (MONDO:0000548) is a cancer with 1 GWAS associations across 1 studies and 4 clinical trials. Top therapeutic interventions include pembrolizumab and epacadostat. A subtype of malignant epithelial tumor of ovary — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
GWAS associations: 1
Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian clear cell cancer
Mondo ID	MONDO:0000548
DOID	DOID:0050934
NCIT	C40077
UMLS	C1518230
MedGen	276544
GARD	0022799
Is cancer (heuristic)	yes

Also known as: malignant ovarian clear cell neoplasm · malignant ovarian clear cell tumor · malignant ovarian clear cell tumour

Data availability: 1 GWAS association (1 study).

Disease family

This is a subtype of malignant epithelial tumor of ovary. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › ovarian epithelial tumor › malignant epithelial tumor of ovary › ovarian clear cell cancer

Related subtypes (5): malignant ovarian Brenner tumor, ovarian endometrial cancer, ovarian carcinoma, mucinous ovarian cancer, malignant ovarian serous tumor

Subtypes (2): ovarian clear cell malignant adenofibroma, ovarian clear cell adenocarcinoma

Genetics & variants

GWAS landscape

1 GWAS associations across 1 studies. Top hits map to 0 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
chr17:36099840	5e-10		T	0.24

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90244171	Dareng EO	2024	1,427	105,724	Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
unknown	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
chr17:36099840				0.484			5e-10	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	2
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03602586	PHASE2	COMPLETED	Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer
NCT02020707	PHASE1	COMPLETED	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
NCT02470559	PHASE1	WITHDRAWN	Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent
NCT00899093	Not specified	TERMINATED	YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEMBROLIZUMAB	4	1
EPACADOSTAT	3	1

Drugs: Pembrolizumab, Epacadostat